Want to see TCRX full AI Analyst Report?
TCRX Stock Chart & Stats
$0.79
-$0.05(-6.19%)
At close: 4:00 PM EDT
$0.79
-$0.05(-6.19%)
Day’s Range― - ―
52-Week Range$0.20 - $2.57
Previous CloseN/A
Volume1.06M
Average Volume (3M)742.15K
Market Cap
$15.66M
Enterprise Value$118.10M
Total Cash (Recent Filing)$100.16M
Total Debt (Recent Filing)$90.89M
Price to Earnings (P/E)―
Beta2.26
Next Earnings
Nov 11, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding63,502,666
10 Day Avg. Volume725,069
30 Day Avg. Volume742,146
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.05
Price to Sales (P/S)12.58
P/FCF Ratio-0.93
Enterprise Value/Market Cap7.54
Enterprise Value/Revenue16.61
Enterprise Value/Gross Profit18.40
Enterprise Value/Ebitda-1.05
Forecast
1Y Price Target
$1.00Price Target Upside26.58% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.99
Revenue Forecast (FY)$4.50M
Bulls Say, Bears Say
Bulls Say
Runway ExtensionThe planned cost reduction and longer cash runway could give TScan more time to advance priority programs without immediately requiring another financing. This improves near-term resource allocation and supports continued development while management concentrates spending on selected assets.
Solid Tumor FocusConcentrating resources on two defined solid-tumor targets creates a clearer development strategy than spreading capital across more programs. Progress toward IND-enabling work can establish important clinical and regulatory milestones for the company’s focused oncology pipeline.
Early Clinical SignalThe reported Cohort C results provide encouraging early evidence for TSC-101’s biological activity and tolerability in hematologic malignancies. Although the program is paused, this signal may preserve asset value and support future partnering or renewed development.
Bears Say
Declining Revenue And Persistent LossesFalling revenue alongside deeply negative operating and net margins shows that TScan has not yet developed a self-sustaining commercial model. Persistent losses increase dependence on financing, partnerships, or successful clinical milestones to support future operations.
Cash Burn And Rising LeverageOngoing cash burn reduces financial flexibility while higher leverage increases the claims on future resources. Together, these trends make it harder for TScan to fund multiple programs internally and heighten the importance of extending runway or securing external capital.
Partnership And Operational SetbacksThe loss of a major collaboration removes potential milestones and royalties, while pausing a Phase 3 study and eliminating internal manufacturing narrow the company’s operating base. These changes reduce near-term development capacity and increase execution risk during the strategic transition.
TScan Therapeutics News
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $0.20 and its highest was $2.57 in the past 12 months.
What is TScan Therapeutics’s market cap?
TScan Therapeutics’s market cap is $15.66M.
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 23 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on Aug 12, 2026. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.253 by $0.023.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -0.19.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 63,502,666 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.253. Following the earnings report the stock price went down -0.387%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Currently, no hedge funds are holding shares in TCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TCRX Stock 12 Month Forecast
Average Price Target
$1.00
▲(26.58% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
ALX Oncology Holdings
―
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
Ownership Overview
16.81% Insiders
5.23% Mutual Funds
31.98% Other Institutional Investors
41.67% Public Companies and
Individual Investors